GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024
GHAPPcast18 Okt 2024

GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024

Welcome back to the final installment of our three-part miniseries on Primary Biliary Cholangitis (PBC) from the GHAPP National 2024 Conference! In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss the most impactful updates in PBC management, treatment goals, and evolving clinical strategies.

A major highlight from this year’s meeting is the shifting treatment paradigm in PBC, moving beyond traditional Poise criteria to a more aggressive target of achieving completely normal alkaline phosphatase (ALKP) levels and a bilirubin of ≤0.6. Experts emphasize that new therapies, including seladelpar and elafibranor, are helping clinicians push treatment goals further, optimizing patient outcomes and disease management.


With the PBC treatment landscape evolving, the panel discusses how the mindset around ALKP reduction has changed, underscoring the importance of setting normalization as the primary goal rather than just achieving a modest reduction. With new and emerging therapies, there is growing excitement about more effective disease control and improved long-term prognosis for patients with PBC.


Watch now to stay ahead on the latest PBC treatment advancements, and don’t forget to check out the full miniseries! For more resources, visit GHAPP.org or download the GHAPP ACE app.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(161)

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Juli 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Juni 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Juni 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-beroende-medberoende
rss-jossan-nina
bullfika
rss-vuxna-pa-latsas
inga-beiga-morsor
not-fanny-anymore
johannes-hansen-podcast
angestpodden
sexnoveller-deluxe
sova-med-dan-horning
rss-viktmedicinpodden
rss-hos-psykologen
halsoveckan-by-tyngre
sa-in-i-sjalen
rss-traningsklubben
hacka-livet
tyngre-radio
rss-angra-inget-3
rss-basta-livet